“The Role of Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia (CLL) and the Achievement of Minimal Residual Disease Negativity in Relapsed Refractory CLL”. 2009. Hematology Meeting Reports (formerly Haematologica Reports) 1 (2). https://doi.org/10.4081/hmr.v1i2.226.